Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Development and Validation of the Diabetes Quality of Life Clinical Trial Questionnaire

Wei Shen, James G. Kotsanos, William J. Huster, Susan D. Mathias, Carol M. Andrejasich and Donald L. Patrick
Medical Care
Vol. 37, No. 4, Lilly Supplement: Global Health Outcomes Research and Customer Applications (Apr., 1999), pp. AS45-AS66
Stable URL: http://www.jstor.org/stable/3767380
Page Count: 22
  • More info
  • Cite this Item
Development and Validation of the Diabetes Quality of Life Clinical Trial Questionnaire
Preview not available

Abstract

Objective. The objective of this study was to develop a valid and reliable health-related quality of life (HRQOL) questionnaire for use in multinational clinical trials of patients with type I and type II diabetes. Methods. Through patient focus groups and expert clinician panels in the United States (US) and France, relevant HRQOL domains for patients with type I and type II diabetes were identified. A draft questionnaire was developed by including validated, widely used generic and diabetes-specific domains and by developing original questions as required. A pilot study (n = 123) was conducted to evaluate the psychometric properties of the draft questionnaire with revisions being subsequently made. Data collected from two multinational clinical trials of patients with type I and type II diabetes were used to further validate and enhance the questionnaire (DQLCTQ). Results. A total of 942 patients were recruited in the clinical trials from Canada, France, Germany, and the United States. The mean age was 33.8 years for patients with type I diabetes (n = 468) and 58.2 years for patients with type II diabetes (n = 474). The mean HbA1c level at baseline was 8.6. The revised version of the questionnaire (DQLCTQ-R) contains a total of 57 questions comprising 8 generic and disease-specific domains, as follows: Physical Function; Energy/Fatigue; Health Distress; Mental Health; Satisfaction; Treatment Satisfaction; Treatment Flexibility; and Frequency of Symptoms. Intraclass correlation coefficients range from 0.74 to 0.90 and Cronbach's alphas range from 0.77 to 0.90. With very few exceptions, all eight domains were able to discriminate between type I and type II diabetes, tight and poor metabolic control, male and female, and good and poor self perceived control of diabetes. Four domains (Treatment Satisfaction, Health/Distress, Mental Health, and Satisfaction) were responsive to clinical change in metabolic control. Conclusion. The DQLCTQ-R is a reliable, valid, and comprehensive HRQOL instrument. It is suitable in multinational clinical trials to evaluate new or alternative treatments for patients with type I and type II diabetes.

Page Thumbnails

  • Thumbnail: Page 
AS45
    AS45
  • Thumbnail: Page 
AS46
    AS46
  • Thumbnail: Page 
AS47
    AS47
  • Thumbnail: Page 
AS48
    AS48
  • Thumbnail: Page 
AS49
    AS49
  • Thumbnail: Page 
AS50
    AS50
  • Thumbnail: Page 
AS51
    AS51
  • Thumbnail: Page 
AS52
    AS52
  • Thumbnail: Page 
AS53
    AS53
  • Thumbnail: Page 
AS54
    AS54
  • Thumbnail: Page 
AS55
    AS55
  • Thumbnail: Page 
AS56
    AS56
  • Thumbnail: Page 
AS57
    AS57
  • Thumbnail: Page 
AS58
    AS58
  • Thumbnail: Page 
AS59
    AS59
  • Thumbnail: Page 
AS60
    AS60
  • Thumbnail: Page 
AS61
    AS61
  • Thumbnail: Page 
AS62
    AS62
  • Thumbnail: Page 
AS63
    AS63
  • Thumbnail: Page 
AS64
    AS64
  • Thumbnail: Page 
AS65
    AS65
  • Thumbnail: Page 
AS66
    AS66